-+ 0.00%
-+ 0.00%
-+ 0.00%

Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky

Barchart·08/10/2026 09:07:00
Listen to the news

Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and suspended adjusted EBITDA guidance. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.